Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort
ACR Open Rheumatology · 2025-03 · 7 (3)
DOI: 10.1002/acr2.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 26.02.2025. Verfasst von Yanjie Hao und 38 weiteren Autor:innen. Beteiligte Einrichtung: The University of Melbourne and St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, and Peking University First Hospital, Beijing, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline, UCB, Bristol-Myers Squibb.
Abstract (Originalsprache)
Objective
In contrast to relapsing‐remitting patterns, persistently active disease (PAD) is a disease activity pattern in patients with systemic lupus erythematosus (SLE) that is inadequately studied. We sought to identify the frequency and determinants of flare and PAD in SLE.
Methods
Flare was defined using the Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SELENA–SLEDAI flare index), and PAD was defined as an SLEDAI‐2K score of ≥4, excluding serology only, on two or more consecutive visits with a maximum six‐month interval. Multivariable logistic regression was used to develop predictive models for flare and PAD, which were tested in an independent validation subset.
Results
Among 3,811 patients over 2.8 (interquartile range 1.0–5.3) years of follow‐up, 2,142 (56.2%) experienced flare and 1,786 (46.9%) had PAD, with 368 (9.7%) experiencing PAD but not flare. The most common flare features were nephritis and arthritis, whereas PAD was most commonly characterized by renal or mucocutaneous activity. After adjusting for prednisone dose and use of antimalarials and immunosuppressants, low gross domestic product in country of residence, smoking, arthritis, nephritis, and low complement levels were predictive for flare, whereas being in a low disease activity state for ≥50% of follow‐up time (LLDAS50) was a protective factor. Renal activity and higher time‐adjusted mean SLEDAI‐2K were predictive of PAD, whereas LLDAS50 was protective. The models developed gave 72.1% and 83.8% correct classification of flare and PAD, respectively, in the validation cohort.
Conclusion
Both flare and PAD are common disease activity patterns in SLE; both predict organ damage accrual but differ in disease features and predictive factors. Because 9.7% of patients experience PAD but not flare, flare measures alone do not adequately capture all patients in whom disease control is suboptimal.
Autor:innen und Institutionen
- The University of Melbourne and St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, and Peking University First Hospital, Beijing, China.
- St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
- Chiang Mai University Hospital, Chiang Mai, Thailand.
- Taichung Veterans General Hospital, Taichung, Taiwan.
- National University Hospital, Singapore.
- Woodlands Health, Singapore.
ORCID-Profile: Yanjie Hao, Worawit Louthrenoo, Jiacai Cho, Laniyati Hamijoyo, Yasuhiro Katsumata, Lanlan Ji, Zhuoli Zhang, Tsutomu Takeuchi, Sang-Cheol Bae, Yoshiya Tanaka, Alberta Hoi, Rangi Kandane-Rathnayake, Eric Morand
Förderung
- GlaxoSmithKline
- UCB
- Bristol-Myers Squibb
- Janssen Research and Development
- AstraZeneca
- EMD Serono
- Eli Lilly Australia
Zitieren
APA
Hao, Y., Hansen, D., Louthrenoo, W., Chen, Y. H., Cho, J., Lateef, A., Hamijoyo, L., Luo, S. F., Wu, Y. J., Navarra, S., Zamora, L., Li, Z., Sockalingam, S., Katsumata, Y., Harigai, M., Ji, L., Zhang, Z., Chan, M., Kikuchi, J., …, & Asia Pacific Lupus Collaboration (2025). Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort. ACR Open Rheumatology, 7(3). https://doi.org/10.1002/acr2.70007
Vancouver
Hao Y, Hansen D, Louthrenoo W, Chen YH, Cho J, Lateef A, et al. Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort. ACR Open Rheumatology. 2025;7(3). doi:10.1002/acr2.70007
BibTeX
@article{Hao2025,
author = {Hao, Yanjie and Hansen, Dylan and Louthrenoo, Worawit and Chen, Yi-Hsing and Cho, Jiacai and Lateef, Aisha and Hamijoyo, Laniyati and Luo, Shue Fen and Wu, Yeong-Jian and Navarra, Sandra and Zamora, Leonid and Li, Zhanguo and Sockalingam, Sargunan and Katsumata, Yasuhiro and Harigai, Masayoshi and Ji, Lanlan and Zhang, Zhuoli and Chan, Madelynn and Kikuchi, Jun and Takeuchi, Tsutomu and Bae, Sang-Cheol and Goldblatt, Fiona and O'Neill, Sean and Ng, Kristine Pek Ling and Basnayake, B M D B and Tugnet, Nicola and Ohkubo, Naoaki and Tanaka, Yoshiya and Tee, Cherica and Tee, Michael and Lau, C S and Li, Ning and Golder, Vera and Hoi, Alberta and Kandane-Rathnayake, Rangi and Morand, Eric and Oon, Shereen and Nikpour, Mandana and Asia Pacific Lupus Collaboration, Asia Pacific Lupus Collaboration},
title = {Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort},
journal = {ACR Open Rheumatology},
year = {2025},
volume = {7},
number = {3},
doi = {10.1002/acr2.70007}
}
EUVIMED